NLRP3 and COVID-19: To confirm inflammasome activation in COVID‐19 patient‐derived macrophages upon S‐protein priming, we first used a chemical genetics approach and pre‐treated COVID‐19 patient‐derived macrophages with MCC950, a selective NLRP3 inhibitor (Coll et al, 2015), which efficiently blocked IL‐1β secretion in S‐protein/nigericin‐stimulated patient cells (Fig 2A).